Debbane Raymond's Form 4 filing
Lexicon Pharmaceuticals, Inc.LXRX · filed Aug 1, 2022
- Accession no.
- 0000899243-22-027157
- Filed
- Aug 1, 2022, 4:15 PM ET
- Trade date
- Aug 1, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $2.46M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Debbane RaymondCIK 0001053890 | Director, 10% Owner |
| Ulys, L.L.C.CIK 0001340098 | Director, 10% Owner |
| Invus US Partners LLCCIK 0001839806 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2022 | Common Stock | PPurchaseAcquired | +982,600 | $2.50 | +$2,456,500 | 5,303,814 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Artal International S.C.A. directly holds 48,433,261 shares of Issuer Common Stock; Invus, L.P. directly holds 35,402,689 shares of Issuer Common Stock; and Invus Public Equities, L.P. directly holds 3,516,214 shares of Issuer Common Stock, which securities are being reported on a separately filed Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.